Medical Developments International (ASX:MVP) Trading Up 4.9%

Share on StockTwits

Medical Developments International Ltd (ASX:MVP)’s stock price was up 4.9% on Monday . The company traded as high as A$6.05 ($4.29) and last traded at A$6.05 ($4.29), approximately 132,578 shares traded hands during mid-day trading. The stock had previously closed at A$5.77 ($4.09).

The business’s 50-day simple moving average is A$5.41 and its two-hundred day simple moving average is A$5.34. The company has a current ratio of 4.21, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $391.68 million and a PE ratio of 373.13.

Medical Developments International Company Profile (ASX:MVP)

Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment in Australia and internationally. The company operates in three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management; Penthrox, a prescription only medicine for acute pain; medical devices; and various veterinary anesthetic machines to veterinarians.

Read More: FAANG Stocks

Receive News & Ratings for Medical Developments International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Developments International and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Genedrive’s  Buy Rating Reiterated at Peel Hunt
Genedrive’s Buy Rating Reiterated at Peel Hunt
Grainger’s  “Buy” Rating Reiterated at Peel Hunt
Grainger’s “Buy” Rating Reiterated at Peel Hunt
Hurricane Energy  Stock Rating Reaffirmed by Berenberg Bank
Hurricane Energy Stock Rating Reaffirmed by Berenberg Bank
Joules  Stock Rating Reaffirmed by Peel Hunt
Joules Stock Rating Reaffirmed by Peel Hunt
Yum China Holdings Inc  Receives Consensus Rating of “Buy” from Analysts
Yum China Holdings Inc Receives Consensus Rating of “Buy” from Analysts
Head-To-Head Analysis: Netlist  versus NVE
Head-To-Head Analysis: Netlist versus NVE


 
© 2006-2019 Zolmax.